Orion Corp
KRX:271560

Watchlist Manager
Orion Corp Logo
Orion Corp
KRX:271560
Watchlist
Price: 104 800 KRW -0.47% Market Closed
Market Cap: 4.1T KRW
Have any thoughts about
Orion Corp?
Write Note

Orion Corp
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Orion Corp
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Orion Corp
KRX:271560
Interest Income Expense
â‚©29.4B
CAGR 3-Years
56%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
CJ CheilJedang Corp
KRX:097950
Interest Income Expense
-â‚©477.8B
CAGR 3-Years
-17%
CAGR 5-Years
-8%
CAGR 10-Years
-8%
Ottogi Corp
KRX:007310
Interest Income Expense
-â‚©16.4B
CAGR 3-Years
-55%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Samyang Foods Co Ltd
KRX:003230
Interest Income Expense
â‚©119.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dongwon Industries Co Ltd
KRX:006040
Interest Income Expense
-â‚©98.3B
CAGR 3-Years
-95%
CAGR 5-Years
-28%
CAGR 10-Years
-29%
Nongshim Co Ltd
KRX:004370
Interest Income Expense
â‚©25.1B
CAGR 3-Years
27%
CAGR 5-Years
34%
CAGR 10-Years
8%
No Stocks Found

Orion Corp
Glance View

Market Cap
4.1T KRW
Industry
Food Products

Perched within the competitive landscape of pharmaceuticals, Orion Corporation has steadily carved its niche since its inception in Finland in 1917. Starting as a small-scale factory operation, Orion has evolved into a pivotal player in the healthcare sector, blending traditional expertise with cutting-edge innovations. The company's core operations pivot around the development, manufacturing, and marketing of human and veterinary pharmaceuticals, as well as active pharmaceutical ingredients (APIs). This dual focus allows Orion not only to reach a diverse market but also ensures a consistent revenue stream, supplemented by its strategic interest in self-care products. The company thrives on its robust research and development arm, constantly seeking innovations in therapeutic areas like central nervous system disorders, oncology, and respiratory diseases. Orion's financial engine hums efficiently through its vertically integrated business model. By managing most of the value chain internally—from drug discovery to production and distribution—Orion secures cost advantages and quality control, translating into a competitive edge in global markets. While Europe remains Orion's stronghold, it strategically seeks growth in regional markets, leveraging partnerships and alliances with international pharmaceutical giants to expand its footprint. This strategy not only augments its own pipeline with licensed products but also fortifies its market position, making it a sustainable player in an industry driven by constant change and regulated rigorously. The corporation's revenue streams thus embody a careful balance of organic product development and strategic collaborations, evidencing a business acumen grounded in long-term vision.

Intrinsic Value
155 742.72 KRW
Undervaluation 33%
Intrinsic Value
Price

See Also

What is Orion Corp's Interest Income Expense?
Interest Income Expense
29.4B KRW

Based on the financial report for Sep 30, 2024, Orion Corp's Interest Income Expense amounts to 29.4B KRW.

What is Orion Corp's Interest Income Expense growth rate?
Interest Income Expense CAGR 3Y
56%

Over the last year, the Interest Income Expense growth was -13%. The average annual Interest Income Expense growth rates for Orion Corp have been 56% over the past three years .

Back to Top